Antiretroviral Therapy Market report is segmented on the basis of drug type and regional & country level. Based upon drug type, global antiretroviral therapy market is classified as Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors and Others.
Antiretroviral Therapy Market is valued at 24.48 USD Billion in 2018 and expected to reach USD 33.83 Billion by 2025 with CAGR of 4.73% over the forecast period.
Antiretroviral therapy is medical prescriptions that treat HIV. These drugs are not applied to kill or cure the virus. Number of ART drugs are present in the market which are when taken in with combination can stop the growth of the virus. Antiretroviral drugs are stated as ARV. Combination ARV therapy is called as highly active ART (HAART). Each type of ARV drugs assaults HIV in a different way. The first class of anti-HIV drugs was the nucleoside reverse transcriptase inhibitors (also known as NRTIs or “nukes”). These drugs block the process where the HIV genetic material is used to create DNA from RNA. Examples of ARV drugs are Zidovudine (Retrovir, AZT), Didanosine (Videx, Videx EC, ddI), Stavudine (Zerit, d4T), Lamivudine (Epivir, 3TC), Abacavir (Ziagen, ABC), Tenofovir, a nucleotide analog (Viread, TDF), Combivir (combination of zidovudine and lamivudine) etc.
The regions covered in this antiretroviral therapy market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Antiretroviral therapy is sub divided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Global Antiretroviral therapy market report covers prominent players like Gilead, ViiV Healthcare, Janssen Pharmaceuticals, F. Hoffmann-La Roche, Abbvie, Boehringer, Ingelheim, Bionor Pharma, Vertex Pharmaceuticals, Mylan and others.
Increasing cases of HIV worldwide is driving the Antiretroviral Therapy Market
According to Clinton health access, globally in 2017, among 36.9 million people living with HIV 21.7 million people living with HIV (PLHIV) were on antiretroviral therapy (ART) treatment, which means approximately 60 % of all those infected were on treatment. AIDS-related deaths have decreased in half since 2007. As for recent statistics, 80 % of pregnant women living with HIV were on treatment. As the cases of HIV are gradually increasing globally, health care industry is depending more on ARV drugs to control the disease, which propels the antiretroviral therapy market. The main factors contributing to the growth of antiretroviral therapy market are increasing prevalence of HIV/AIDS, growing antiretroviral treatment coverage rate, and increase in availability of novel drugs with better efficiency, increasing medical spending and governments steps to cure HIV drives the growth of antiretroviral drugs. In the largest HIV burdened country South Africa, about 85% of people living with HIV (PLHIV) knew their status and 71% people were on ART, which shows the extensive use of antiretroviral drugs in treatment of HIV. But increasing portfolio of generic antiretroviral drugs is impacting the market growth.
North America is dominating the antiretroviral therapy Market
North America is dominating the antiretroviral market due to factors such as high ART coverage rate and more stress on prescribed branded drugs. Additionally, the US is focusing more on increasing the ability to identify the HIV-infected patients by launching the HIV care continuum initiative. Besides, the enrolment of HIV patients to the comprehensive health insurance program is increasing due to the establishment of the affordable care act in 2010 in the US. All these steps in turn, are resulting in an increased number of infected individuals selecting ART for treatment which propels the antiretroviral therapy market in North America.
The consumption of ARV in African region is increasing due to growing number of HIV cases, low price of ARV, initiatives take by international bodies such as WHO, and international NGOs are the factors for rapid growth of antiretroviral therapy market in this region. For example, Generic drugs of ARV has share of 70 % of the total purchase volume in South Africa and their price was 24 % higher than the rest of sub-Saharan Africa. As for East Asia and Pacific and South Asia they are paying 10 % and 13 % less than sub-Saharan Africa respectively. Compared to low income countries, ARVs prices were 14 % and 48 % higher in lower-middle and upper-middle income countries which is also affecting the market in that region accordingly.
Key Benefits for Market Reports –
By Drug Type:
By Regional & Country Analysis
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2023-24 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®